414 related articles for article (PubMed ID: 30661630)
1. Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol.
Stolk E; Ludwig K; Rand K; van Hout B; Ramos-Goñi JM
Value Health; 2019 Jan; 22(1):23-30. PubMed ID: 30661630
[TBL] [Abstract][Full Text] [Related]
2. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol.
Oppe M; Devlin NJ; van Hout B; Krabbe PF; de Charro F
Value Health; 2014 Jun; 17(4):445-53. PubMed ID: 24969006
[TBL] [Abstract][Full Text] [Related]
3. Does the Introduction of the Ranking Task in Valuation Studies Improve Data Quality and Reduce Inconsistencies? The Case of the EQ-5D-5L.
Ramos-Goñi JM; Rand-Hendriksen K; Pinto-Prades JL
Value Health; 2016 Jun; 19(4):478-86. PubMed ID: 27325340
[TBL] [Abstract][Full Text] [Related]
4. Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.
Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
Value Health; 2019 Jan; 22(1):38-44. PubMed ID: 30661632
[TBL] [Abstract][Full Text] [Related]
5. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
[TBL] [Abstract][Full Text] [Related]
6. Valuation of the EQ-5D-5L with composite time trade-off for the German population - an exploratory study.
Ludwig K; von der Schulenburg JG; Greiner W
Health Qual Life Outcomes; 2017 Feb; 15(1):39. PubMed ID: 28219389
[TBL] [Abstract][Full Text] [Related]
7. Valuing health-related quality of life: An EQ-5D-5L value set for England.
Devlin NJ; Shah KK; Feng Y; Mulhern B; van Hout B
Health Econ; 2018 Jan; 27(1):7-22. PubMed ID: 28833869
[TBL] [Abstract][Full Text] [Related]
8. EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set.
Kreimeier S; Greiner W
Value Health; 2019 Jan; 22(1):31-37. PubMed ID: 30661631
[TBL] [Abstract][Full Text] [Related]
9. Quality Control Process for EQ-5D-5L Valuation Studies.
Ramos-Goñi JM; Oppe M; Slaap B; Busschbach JJ; Stolk E
Value Health; 2017 Mar; 20(3):466-473. PubMed ID: 28292492
[TBL] [Abstract][Full Text] [Related]
10. UK Valuation of EQ-5D-5L, a Generic Measure of Health-Related Quality of Life: A Study Protocol.
Rowen D; Mukuria C; Bray N; Carlton J; Cooper S; Longworth L; Meads D; O'Neill C; Yang Y
Value Health; 2023 Nov; 26(11):1625-1635. PubMed ID: 37722593
[TBL] [Abstract][Full Text] [Related]
11. Preparatory study for the revaluation of the EQ-5D tariff: methodology report.
Mulhern B; Bansback N; Brazier J; Buckingham K; Cairns J; Devlin N; Dolan P; Hole AR; Kavetsos G; Longworth L; Rowen D; Tsuchiya A
Health Technol Assess; 2014 Feb; 18(12):vii-xxvi, 1-191. PubMed ID: 24568945
[TBL] [Abstract][Full Text] [Related]
12. Dutch Tariff for the Five-Level Version of EQ-5D.
M Versteegh M; M Vermeulen K; M A A Evers S; de Wit GA; Prenger R; A Stolk E
Value Health; 2016 Jun; 19(4):343-52. PubMed ID: 27325326
[TBL] [Abstract][Full Text] [Related]
13. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
14. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
Yang F; Devlin N; Luo N
Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
[TBL] [Abstract][Full Text] [Related]
15. How Prevalent Are Implausible EQ-5D-5L Health States and How Do They Affect Valuation? A Study Combining Quantitative and Qualitative Evidence.
Yang Z; Feng Z; Busschbach J; Stolk E; Luo N
Value Health; 2019 Jul; 22(7):829-836. PubMed ID: 31277831
[TBL] [Abstract][Full Text] [Related]
16. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe.
Golicki D; Jakubczyk M; Graczyk K; Niewada M
Pharmacoeconomics; 2019 Sep; 37(9):1165-1176. PubMed ID: 31161586
[TBL] [Abstract][Full Text] [Related]
17. Less Is More: Cross-Validation Testing of Simplified Nonlinear Regression Model Specifications for EQ-5D-5L Health State Values.
Rand-Hendriksen K; Ramos-Goñi JM; Augestad LA; Luo N
Value Health; 2017; 20(7):945-952. PubMed ID: 28712624
[TBL] [Abstract][Full Text] [Related]
18. United States Valuation of EQ-5D-5L Health States Using an International Protocol.
Pickard AS; Law EH; Jiang R; Pullenayegum E; Shaw JW; Xie F; Oppe M; Boye KS; Chapman RH; Gong CL; Balch A; Busschbach JJV
Value Health; 2019 Aug; 22(8):931-941. PubMed ID: 31426935
[TBL] [Abstract][Full Text] [Related]
19. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK.
Swinburn P; Lloyd A; Boye KS; Edson-Heredia E; Bowman L; Janssen B
Value Health; 2013 Dec; 16(8):1156-62. PubMed ID: 24326169
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]